Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tracy C Kuo

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Plos One|August 23, 2018
ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profileSteven E Kauder, Tracy C Kuo, Ons Harrabi, et al.
Science Translational Medicine|August 8, 2014
Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosisArumugam Palanichamy, Leonard Apeltsin, Tracy C Kuo, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 30, 2011
Naive antibody gene-segment frequencies are heritable and unaltered by chronic lymphocyte ablationJacob Glanville, Tracy C Kuo, H-Christian von Büdingen, et al.
Journal of Hematology & Oncology|December 1, 2020
Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activityTracy C Kuo, Amy Chen, Ons Harrabi, et al.
Mabs|July 2, 2019
Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPαJanet Sim, Jonathan T Sockolosky, Emma Sangalang, et al.
The Journal of Clinical Investigation|November 20, 2012
B cell exchange across the blood-brain barrier in multiple sclerosisH-Christian von Büdingen, Tracy C Kuo, Marina Sirota, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 22, 2019
Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple MyelomaCesar Sommer, Bijan Boldajipour, Tracy C Kuo, et al.
The Lancet. Oncology|November 18, 2021
Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion studyNehal J Lakhani, Laura Q M Chow, Justin F Gainor, et al.
Molecular Cancer Therapeutics|August 23, 2019
Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple MyelomaSiler H Panowski, Tracy C Kuo, Yi Zhang, et al.
Nature Medicine|January 14, 2022
Anti-GD2 synergizes with CD47 blockade to mediate tumor eradicationJohanna Theruvath, Marie Menard, Benjamin A H Smith, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Plos One|August 23, 2018
ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profileSteven E Kauder, Tracy C Kuo, Ons Harrabi, et al.
Science Translational Medicine|August 8, 2014
Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosisArumugam Palanichamy, Leonard Apeltsin, Tracy C Kuo, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 30, 2011
Naive antibody gene-segment frequencies are heritable and unaltered by chronic lymphocyte ablationJacob Glanville, Tracy C Kuo, H-Christian von Büdingen, et al.
Journal of Hematology & Oncology|December 1, 2020
Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activityTracy C Kuo, Amy Chen, Ons Harrabi, et al.
Mabs|July 2, 2019
Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPαJanet Sim, Jonathan T Sockolosky, Emma Sangalang, et al.
The Journal of Clinical Investigation|November 20, 2012
B cell exchange across the blood-brain barrier in multiple sclerosisH-Christian von Büdingen, Tracy C Kuo, Marina Sirota, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 22, 2019
Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple MyelomaCesar Sommer, Bijan Boldajipour, Tracy C Kuo, et al.
The Lancet. Oncology|November 18, 2021
Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion studyNehal J Lakhani, Laura Q M Chow, Justin F Gainor, et al.
Molecular Cancer Therapeutics|August 23, 2019
Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple MyelomaSiler H Panowski, Tracy C Kuo, Yi Zhang, et al.
Nature Medicine|January 14, 2022
Anti-GD2 synergizes with CD47 blockade to mediate tumor eradicationJohanna Theruvath, Marie Menard, Benjamin A H Smith, et al.
Pageof 2